Appili Therapeutics (APLIF) announced the United States Patent and Trademark Office and the Mexican Patent Office have granted new patent claims protecting its oral formulation of metronidazole, LIKMEZ. The newly granted patents include: U.S. patent no. 20230086660A1 – Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same; Mexican patent no. 2020007494 – Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same. The two new patents, set to expire in 2039 provide comprehensive protection for LIKMEZ, covering its unique taste masked composition and accessible therapeutic applications.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLIF:
- Appili Therapeutics CEO to Discuss Strategic Growth and Funding Initiatives
- Appili Therapeutics CEO to join Aditxt CEO for weekly update on April 4
- Biotech Alert: Searches spiking for these stocks today
- Appili Therapeutics Seeks $117.5 Million in Federal Funding for Infectious Disease Treatments
- Appili Therapeutics announces submission of government funding proposals
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue